RNA interference in ocular indications

1. A method for delivering a nucleic acid to an eye of a subject in need thereof, comprising

administering to the eye of the subject an sd-rxRNA®, in an effective amount to promote RNA interference by the sd-rxRNA® in the eye

wherein the sd-rxRNA® comprises a guide strand and a passenger strand, wherein the sd-rxRNA® includes a double stranded region and a single stranded region, wherein the double stranded region is from 8-15 nucleotides long, wherein the single stranded region is at the 3′ end of the guide strand and is 4-12 nucleotides long, wherein the single stranded region contains 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 phosphorothioate modifications, wherein at least 40% of the nucleotides of the isolated double stranded nucleic acid molecule are modified, wherein the sd-rxRNA has one end that is blunt, and wherein the sd-rxRNA is directed against a sequence comprising at least 12 contiguous nucleotides of a sequence selected from SEQ ID NOs: 1-182.

2. The method of claim 1 , wherein the administration of the sd-rxRNA® is intravitreal.

3. The method of claim 1 , wherein the method is a method for treating an ocular disorder, optionally wherein the ocular disorder is selected from the group consisting of: vascular leakage, neovascularization, age-related macular degeneration (AMD), choroidal neovascularization (wet AMD), geographic atrophy (advanced dry AMD), early-to-intermediate dry AMD, post surgical cystoid macular edema (CME), nonproliferative diabetic retinopathy (NPDR), diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), proliferative diabetic retinopathy (PDR), glaucoma, neovascular glaucoma (NVG), retinopathy of prematurity (ROP), fibroproliferative retinal disease, proliferative vitreoretinopathy (PVR), epiretinal membranes/vitreomacular adhesions, retinal degenerative disease, retinitis pigmentosa, retinal vascular occlusive disorders, retinal vein occlusion, retinal artery occlusion, retinoblastoma, trabeculectomy failure due to scarring, and uveitis.

4. The method of claim 3 , wherein the ocular disorder is proliferative vitreoretinopathy (PVR).

5. The method of claim 1 , wherein a second sd-rxRNA® that is directed against a gene encoding for a different protein is also administered to the eye of the subject.

6. The method of claim 5 , wherein the second sd-rxRNA® comprises an sd-rxRNA® directed against CTGF.

7. The method of claim 1 , wherein the sd-rxRNA® is hydrophobically modified, optionally wherein the sd-rxRNA® is linked to one or more hydrophobic conjugates and/or the sd-rxRNA® includes at least one 5-methyl C or U modifications.

8. A method for delivering a nucleic acid to an eye of a subject in need thereof, comprising

administering to the eye of the subject an sd-rxRNA®, in an effective amount to promote RNA interference by the sd-rxRNA® in the eye

wherein the sd-rxRNA® comprises a guide strand and a passenger strand, wherein the sd-rxRNA® includes a double stranded region and a single stranded region, wherein the double stranded region is from 8-15 nucleotides long, wherein the single stranded region is at the 3′ end of the guide strand and is 4-12 nucleotides long, wherein the single stranded region contains 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 phosphorothioate modifications, wherein at least 40% of the nucleotides of the isolated double stranded nucleic acid molecule are modified,

wherein the sd-rxRNA is directed against a gene encoding CTGF and wherein the sense strand of the sd-rxRNA® comprises at least 12 contiguous nucleotides of the sequence of SEQ ID NO:967 (mU.mU. G.mC. A.mC.mC.mU.mU.mU.mC.mU*mA*mA.TEG-Chl), 969 (mU.mU. G.mC. A.mC.mC.mU.mU.mU.mC.mU*mA*mA.TEG-Chl), 949 (G.mC. A.mC.mC.mU.mU.mU.mC.mU. A*mG*mA.TEG-Chl), 1011 (G.mU. G. A.mC.mC. A. A. A. A. G*mU*mA.TEG-Chl), 1013 (G.mU. G. A.mC.mC. A. A. A. A. G*mU*mA.TEG-Chl), 1023 (G.mU. G. A.mC.mC. A. A. A. A. G*mU*mA.Teg-Chl), or 1025 (G.mU. G. A.mC.mC. A. A.mA. A. G*mU*mA.Teg-Chl) and/or wherein the antisense strand of the sd-rxRNA® comprises at least 12 contiguous nucleotides of the sequence of SEQ ID NO:968 (P.mU.fU. A. G. A.mA. A. G. G.fU. G.fC. A. A* A*fC* A*mA*mG* G.), 970 (P.mU.fU. A. G. A.mA. A. G. G.fU. G.fC.mA. A*mA*fC* A*mA*mG* G.), 950 (P.mU.fC.fU. A. G.mA. A.mA. G. G.fU. G.mC* A*mA* A*mC* A* U.), 1012 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.mC. A.mC* A*mC*mU*mC*mU* C.), 1014 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.fC. A.mC* A*fC*mU*fC*mU* C.), 1024 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.fC. A.mC* A*fC*mU*fC*mU* C.), or 1026 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.mC. A.mC* A*mC*mU*mC*mU* C.).

9. The method of claim 8 , wherein the sense strand of the sd-rxRNA® comprises SEQ ID NO:967 (mU.mU. G.mC. A.mC.mC.mU.mU.mU.mC.mU*mA*mA.TEG-Chl) and the antisense strand of the sd-rxRNA® comprises SEQ ID NO:968 (P.mU.fU. A. G. A.mA. A. G. G.fU. G.fC. A. A* A*fC* A*mA*mG* G.), the sense strand of the sd-rxRNA® comprises SEQ ID NO:969 (mU.mU. G.mC. A.mC.mC.mU.mU.mU.mC.mU*mA*mA.TEG-Chl) and the antisense strand of the sd-rxRNA® comprises SEQ ID NO:970 (P.mU.fU. A. G. A.mA. A. G. G.fU. G.fC.mA. A*mA*fC* A*mA*mG* G.), the sense strand of the sd-rxRNA® comprises SEQ ID NO:949 (G.mC. A.mC.mC.mU.mU.mU.mC.mU. A*mG*mA.TEG-Chl) and the antisense strand of the sd-rxRNA® comprises SEQ ID NO:950 (P.mU.fC.fU. A. G.mA. A.mA. G. G.fU. G.mC* A*mA* A*mC* A* U.), the sense strand of the sd-rxRNA® comprises SEQ ID NO:1011 (G.mU. G. A.mC.mC. A. A. A. A. G*mU*mA.TEG-Chl) and the antisense strand of the sd-rxRNA® comprises SEQ ID NO:1012 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.mC. A.mC* A*mC*mU*mC*mU* C.), the sense strand of the sd-rxRNA® comprises SEQ ID NO:1013 (G.mU. G. A.mC.mC. A. A. A. A. G*mU*mA.TEG-Chl) and the antisense strand of the sd-rxRNA® comprises SEQ ID NO:1014 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.fC. A.mC* A*fC*mU*fC*mU* C.), the sense strand of the sd-rxRNA® comprises SEQ ID NO:1023 (G.mU. G. A.mC.mC. A. A. A. A. G*mU*mA.Teg-Chl) and the antisense strand of the sd-rxRNA® comprises SEQ ID NO:1024 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.fC. A.mC* A*fC*mU*fC*mU* C.), or the sense strand of the sd-rxRNA® comprises SEQ ID NO:1025 (G.mU. G. A.mC.mC. A. A.mA. A. G*mU*mA.Teg-Chl) and the antisense strand of the sd-rxRNA® comprises SEQ ID NO: 1026 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.mC. A.mC* A*mC*mU*mC*mU* C.).

10. The method of claim 8 , wherein the method is a method for treating an ocular disorder, optionally wherein the ocular disorder is selected from the group consisting of: vascular leakage, neovascularization, age-related macular degeneration (AMD), choroidal neovascularization (wet AMD), geographic atrophy (advanced dry AMD), early-to-intermediate dry AMD, post surgical cystoid macular edema (CME), nonproliferative diabetic retinopathy (NPDR), diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), proliferative diabetic retinopathy (PDR), glaucoma, neovascular glaucoma (NVG), retinopathy of prematurity (ROP), fibroproliferative retinal disease, proliferative vitreoretinopathy (PVR), epiretinal membranes/vitreomacular adhesions, retinal degenerative disease, retinitis pigmentosa, retinal vascular occlusive disorders, retinal vein occlusion, retinal artery occlusion, retinoblastoma, trabeculectomy failure due to scarring, and uveitis.

11. The method of claim 8 , wherein a second sd-rxRNA® that is directed against a gene encoding for a different protein is also administered to the eye of the subject.

12. The method of claim 11 , wherein the second sd-rxRNA® comprises an sd-rxRNA® directed against VEGF.

13. The method of claim 12 , wherein the sd-rxRNA® is directed against a sequence selected from the sequences within Table 2, optionally wherein the sd-rxRNA® is directed against a sequence comprising at least 12 contiguous nucleotides of a sequence selected from the sequences within Table 2.

14. The method of claim 8 , wherein the sd-rxRNA® is hydrophobically modified, optionally wherein the sd-rxRNA® is linked to one or more hydrophobic conjugates and/or the sd-rxRNA® includes at least one 5-methyl C or U modifications.